The committee will discuss whether compounding pharmacies can make the peptides in question. But FDA scientists say there’s little — if any — evidence they work in humans.

APhA urges FDA to put patient safety first in review of peptide substances

The committee will discuss whether compounding pharmacies can make the peptides in question. But FDA scientists say there’s little — if any — evidence they work in humans.

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.